Sustained GLP-1 receptor agonist therapy improved glycemic control and modestly reduced all-cause mortality compared to DPP-4 inhibitor therapy in type 2 diabetes.
Does sustained GLP-1 RA treatment improve glycemic control and reduce all-cause mortality compared to DPP-4 inhibitors in patients with type 2 diabetes?
In a real-world target trial emulation, sustained GLP-1 RA therapy demonstrated superior glycemic control and a modest mortality benefit compared to DPP-4 inhibitors in patients with type 2 diabetes.
Absolute Event Rate: 0% vs 0%
Within the limitations of this nationwide study and the available data, sustained GLP-1 RA therapy provided superior glycemic control and was associated with a modest mortality benefit compared with DPP-4i therapy.
Sørensen et al. (Wed,) reported a other. Sustained GLP-1 receptor agonist therapy improved glycemic control and modestly reduced all-cause mortality compared to DPP-4 inhibitor therapy in type 2 diabetes.